Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

New HCPCS Code Added for Anifrolumab-fnia, 1 mg

From the College  |  May 6, 2022

Effective for dates of service on or after April 1, the Healthcare Common Procedure Coding System (HCPCS) code J0491 is valid for billing 1 mg anifrolumab-fnia.

CVS Issues Revised Prior Authorization Forms

From the College  |  May 5, 2022

In response to ACR and provider concerns about administrative burden, CVS Caremark has issued a streamlined version of its prior authorization forms for many biologic drugs.

Remission Definitions in RA: Common Questions & Implications for Clinical Practice

Samantha C. Shapiro, MD  |  May 5, 2022

A recent editorial provides new insights by reexamining the definitions of remission for rheumatoid arthritis and outlining concerns with the use of specific metrics for remission in clinical trials.

Risk of Adverse Outcomes Due to COVID-19 May Be Lower with TNF Inhibitor Monotherapy

Katie Robinson  |  May 5, 2022

Findings support the continued use of TNF inhibitor monotherapy in individuals with immune-mediated inflammatory diseases. In the study, these patients had a lower risk of hospitalization or death caused by COVID-19 than patients on other commonly prescribed treatment regimens

Anifrolumab Promising for Sustained Low Disease Activity in Patients with Lupus

Michele B. Kaufman, PharmD, BCGP  |  May 5, 2022

ACR CONVERGENCE 2021—Using pooled data from the TULIP-1 and TULIP-2 clinical trials, researchers set out to identify whether more patients with systemic lupus erythematosus (SLE) being treated with anifrolumab achieved a low disease activity state than patients with SLE who received placebo.1-3 An analysis of the data was presented at ACR Convergence 2021 by Eric…

New Tech Provides Insights Into the Pathogenesis of Psoriatic Arthritis

Maria de la Luz Garcia-Hernandez, PhD, & Christopher Ritchlin, MD, MPH  |  May 5, 2022

The etiology of psoriatic arthritis (PsA) is poorly understood but current evidence supports an interaction between genetic and environmental factors that coalesce to promote local tissue inflammation.1-3 The pivotal cytokines that underlie the local inflammatory response in a wide range of tissues are interleukin (IL) 23, IL-17 and tumor necrosis factor (TNF).4 The central contribution…

Looking to Psoriatic Arthritis History to Disrupt Current Thinking

Rebecca H. Haberman, MD, & Jose U. Scher, MD  |  May 4, 2022

As the cloud moved away from the tent, Miriam’s skin suddenly became diseased, as white as snow. When Aaron turned toward her, he saw that she was diseased. —Numbers 12:10 For 29 years he [Fray Pedro de Urraca] was afflicted by … pain, suffering it at once in all the joints of his body, with…

Outcomes in Patients with Rheumatic Diseases & COVID-19

Arthritis & Rheumatology  |  April 26, 2022

Background & objectives: Patients with rheumatic and musculoskeletal diseases (RMDs) may be at an increased risk of SARS-CO-V2 infection as a result of underlying disease, associated comorbidities and use of potentially immunosuppressive treatments. Further, concern exists regarding whether individuals with rheumatic diseases potentially experience more severe COVID-19 and poorer outcomes. This study was undertaken to…

DNA Methylation Profiles May Shed Light on the Evolution of Arthritis in Patients

Lara C. Pullen, PhD  |  April 26, 2022

A study found DNA methylation profiling may predict if a patient will progress from a diagnosis of undifferentiated arthritis to that of rheumatoid arthritis (RA). The findings also suggest a pre-established epigenetic signature exists in patients diagnosed with undifferentiated arthritis that evolves into RA.

ACR Leaders to Meet with Members of Congress at May 12 Capitol Hill Event

From the College  |  April 25, 2022

The meetings will focus on legislation affecting rheumatology, including bills on graduate medical education and use of copay assistance funds.

  • « Previous Page
  • 1
  • …
  • 106
  • 107
  • 108
  • 109
  • 110
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences